Shkreli is interesting, he spent a lot of effort trying to show the lay investor how to cut through the BS in fda phase trial documentation. Not for himself, really, but for the general public.
As someone actively on the side of trying to figure out how to manufacture cheaper drugs, I have a lot of respect for him for being vocal (if in a self-serving juvenile fashion) about how the patenting and fda orphan drug system is broken and captured by industry. I can only imagine he was kind of pulling the same trick with the SEC, but miscalculated as he had burned all of his political capital on the pharma shenanigans.
In one case, he lobbied the FDA to not approve a drug. Not because it wasn't safe, or effective. In fact it was safe, and effective, and cheaper than alternatives out there.
It's that it wasn't -his- drug. His company had the market-leading alternative.
So he lobbied against approving safer medicine because it would cost him profit.
As someone actively on the side of trying to figure out how to manufacture cheaper drugs, I have a lot of respect for him for being vocal (if in a self-serving juvenile fashion) about how the patenting and fda orphan drug system is broken and captured by industry. I can only imagine he was kind of pulling the same trick with the SEC, but miscalculated as he had burned all of his political capital on the pharma shenanigans.